Ovarian carcinoma patients with a tumor BRCA-like genomic copy number aberration profile benefit from maintenance olaparib/bevacizumab therapy in the PAOLA-1 randomized controlled trial. https://www.medrxiv.org/content/10.1101/2023.05.27.23290631
Ovarian carcinoma patients with a tumor BRCA-like genomic copy number aberration profile benefit from maintenance olaparib/bevacizumab therapy in the PAOLA-1 randomized controlled trial. https://www.medrxiv.org/content/10.1101/2023.05.27.23290631